Jinwon Life Sciences Applies to MFDS for Phase 2 Clinical Trial of Oral COVID-19 Treatment
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 1st that it has submitted an application for clinical trial approval to the Ministry of Food and Drug Safety for the Phase 2 clinical study of GLS-1027, an oral treatment for COVID-19.
The clinical trial applied for by GeneOne Life Science is titled “A dose-escalation, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of orally administered GLS-1027 for the prevention of severe pneumonia caused by coronavirus disease 2019 (COVID-19) infection.”
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- Key Figures Jo Taeyong and Kim Yonghyun to Receive First Trial Verdicts Next Week in "December 3 Martial Law" Case... Special Prosecutor’s Results Expected
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The company stated, “GLS-1027 is an oral capsule formulation whose safety has already been confirmed through clinical studies in healthy adults,” adding, “Since GLS-1027 suppresses cytokines, which are inflammation-inducing substances, it is expected to serve as a proactive treatment that can be taken after COVID-19 diagnosis to prevent progression to severe lung disease and achieve full recovery.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
